- Details
- Fernando Maluf joins Charles Ryan to discuss the data from the first Prostate Cancer Global Consensus Conference for Developing Countries. This was a tremendous achievement in which more than a hundred physicians from all over the world, particularly from developing countries in Latin America, Africa, and the Middle East participated. Physicians that participated included several specialties: urol...
|
- Details
- In the era that genomics and genetics are really making an impact to clinical practice and with the recent positive results of the PROfound study, Alicia Morgans and Colin Pritchard have a discussion thinking about this data, how do we implement it, and how do we work with our pathologists to make things happen? Colin highlights this game-changing genomic markers data, particularly for homologous...
|
- Details
- During the Management of Metastatic Castration-sensitive/naive Prostate Cancer session at the 2019 Advanced Prostate Cancer Consensus Conference, William Oh presented the use of androgen deprivation therapy (ADT) alone vs. the use of ADT in addition to one of the available systemic therapies for metastatic prostate cancer. Biography: William K. Oh, MD, Chief Medical Officer (CMO), of the Prostate...
|
- Details
- During the Management of metastatic castration-sensitive/naive prostate cancer session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC), Matthew Sydes presented a statisticians' perspective on Addition of AR pathway inhibitors vs. docetaxel. Video Length 10:53 minutes Biography: Matthew R Sydes, MSc CStat CSci, MRC Clinical Trials Unit at UCL London Related Content: Written Confer...
|
- Details
- During the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) Himisha Beltran presented an overview looking into the future of oligometastatic disease, and where she predicts we will be in two years’ time. Her presentation focused on refined clinical definitions for disease stratification, nominated molecular biomarkers to capture biologic disease states and defined goals of care for impro...
|
- Details
- Fred Saad presented on bone and bone metastases at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 focusing on the prevention and treatment of osteoporosis. Given the relationship between ADT and bone loss, previous studies have established that ADT leads to increased fracture rates. Along with a proposed approached for men on ADT, Dr. Saad recommends the use of Fracture Risk Assess...
|
- Details
- Thomas Steuber spoke on the role of surgery in the setting of metastatic prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He highlights the advantages of surgical removal of the primary tumor, the effects of surgery on cancer-specific survival and overall survival compared with no local treatment in the setting of de novo metastatic prostate cancer, and prospectiv...
|
- Details
- Alicia Morgans and Ian Davis presented an update on the IRONMAN study, an International Registry for Men with Advanced Prostate Cancer at the Advanced Prostate Cancer Consensus Conference (APCCC). The ultimate goal of this project is to provide the most elaborate description and understanding of patients with advanced prostate cancer. The project includes a description of treatment changes, advers...
|
- Details
- Declan Murphy presented on node-positive prostate cancer focusing on the staging of high-risk/locally advanced prostate cancer session on Node-positive Prostate Cancer (N1 but M0), How to Treat Men with Newly Diagnosed cN1 cM0 at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. He elaborates on the performance of conventional imaging for staging clinical node status and the evidence...
|
- Details
- Nick James presented on the systemic therapy options for men with node-positive hormone-sensitive prostate cancer (HSPC), including whether the primary tumor should be treated, and which treatments can be combined at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Also highlighted in his presentation is the role of docetaxel in M0 and M1 HSP, abiraterone’s role in high-risk M0 HSPC...
|
